Publicaciones en colaboración con investigadores/as de Semmelweis University (14)

2023

  1. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  2. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  2. Genetically determined telomere length and multiple myeloma risk and outcome

    Blood Cancer Journal, Vol. 11, Núm. 4

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

    BMC Cancer, Vol. 21, Núm. 1

  5. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    British Journal of Haematology, Vol. 193, Núm. 3, pp. 561-569

2019

  1. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

    New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

2017

  1. Rivaroxaban with or without aspirin in stable cardiovascular disease

    New England Journal of Medicine, Vol. 377, Núm. 14, pp. 1319-1330

2015

  1. Future research and clinical directions in the field of men's mental health: The madrid declaration

    Neurobiology of Men's Mental Health (Nova Science Publishers, Inc.), pp. 323-327

  2. Type 2 diabetes-related variantsinfluence the risk of developing multiple myeloma: Results from the IMMEnSE consortium

    Endocrine-Related Cancer, Vol. 22, Núm. 4, pp. 545-559

2014

  1. Future research and clinical directions in the field of men's mental health: The Madrid declaration

    Frontiers in Public Health

  2. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations - An extensive replication of the associations from the candidate gene era

    Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 4, pp. 670-674